Please login to the form below
UCB’s Mark Bodmer elected to BIA board
Will hold the position for a three-year fixed term
UCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).
Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.
As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.
Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.
His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.
Featured jobs
-
Senior Medical Writer
-
Salary TBC
- Medical Writer/ Senior Medical Writer opportunities – Macclesfie...
-
competitive salary and benefits package
Subscribe to our email news alerts
- Celgene says no to Mereo’s cancer drug etigilimab
- Digital division NHSX looks to improve experience for doctors as well as patients
- AbbVie’s upadacitinib tops Humira again in arthritis trial
- Syncona start-up Quell Therapeutics appoints chief exec
- Aimmune wins over ICER for peanut allergy product
- Sobi takes ownership of rare disease drug Gamifant for $518m
PMHub
Frontera Group
Welcome to Frontera Group where our agencies immerse you in the world of the patient...
Latest intelligence
- Women Leaders in UK Healthcare: Liz Henderson
- Merck UK & Ireland’s MD on her ‘non-linear’ career and the importance of mentoring...
- Webinar: Usability and UX: You’ve been asked to test...What next?
- Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
- Event: EphMRA Annual Conference
- We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Quick links
Infographics
